Search results: Sage Journals

Open accessResearch articleFirst published October, 2024

Understanding Australian Pharmacists’ Perceptions on the Utilisation of Oral 5-HT3 Antagonists as Pharmacist-Only Anti-Emetics in Comparison to Oral D2 Antagonists

Aiden Hendry, Jack Janetzki, Wern Chern Chai

Journal of Pharmacy Practice

Restricted accessResearch articleFirst published May, 1996

5-HT3 receptor antagonism and psychoactivity

John T. Sullivan, Kenzie L. Preston, Margaret P. Testa [...]

Journal of Psychopharmacology

Restricted accessResearch articleFirst published December, 2012

Effectiveness of Palonosetron Versus Other Serotonin 5-HT3 Receptor Antagonists in Triple Antiemetic Regimens During Multiday Highly Emetogenic Chemotherapy

Kyung Im Kim, Dong Eun Lee, Inhye Cho [...]

Annals of Pharmacotherapy

Open accessResearch articleFirst published December, 2016

5-HT3 receptor antagonists for the prevention of postoperative shivering: a meta-analysis

Chengmao Zhou, Yu Zhu, Zhen Liu [...]

Journal of International Medical Research

Restricted accessResearch articleFirst published August, 2006

Cilansetron: A New Selective Serotonin Type 3 (5-HT3)-Receptor Antagonist for the Treatment of Irritable Bowel Syndrome in Males and Females

Brent A. Albertson

Hospital Pharmacy

Free accessResearch articleFirst published September, 2015

Beyond the 5-HT3 receptors

S Khalifeh, G Fakhfouri, SE Mehr [...]

Human & Experimental Toxicology

Restricted accessResearch articleFirst published September, 2017

Economic evaluation of 5-HT3 receptor antagonists in combination with dexamethasone for the prevention of ‘overall’ nausea and vomiting following highly emetogenic chemotherapy in Chinese adult patients

Qiong Du, Qing Zhai, Bin Zhu [...]

Journal of Oncology Pharmacy Practice

Restricted accessResearch articleFirst published December, 1990

Prevention of Nausea and Vomiting in Cisplatin-Treated Patients by a Selective 5-Hydroxytryptamine (5-HT3) Receptor Antagonist,ICS 205-930

Luigi Dogliotti, Roberto Faggiuolo, Alfredo Berruti [...]

Tumori Journal

Restricted accessOtherFirst published January, 2004

Cancer Patients Submitted to Innovative Chemotherapeutic Agents of Intermediate Emetogenic Potential: Antiemetic Prescriptions and Incidence of Emesis

Verena De Angelis

Tumori Journal

Restricted accessCase reportFirst published June, 2012

Possible anaphylaxis to palonoestron

John M Pietkiewicz

Journal of Oncology Pharmacy Practice

Open accessResearch articleFirst published October, 2024

Understanding Australian Pharmacists’ Perceptions on the Utilisation of Oral 5-HT3 Antagonists as Pharmacist-Only Anti-Emetics in Comparison to Oral D2 Antagonists

Aiden Hendry, Jack Janetzki, Wern Chern Chai

Journal of Pharmacy Practice

Restricted accessResearch articleFirst published May, 1996

5-HT3 receptor antagonism and psychoactivity

John T. Sullivan, Kenzie L. Preston, Margaret P. Testa [...]

Journal of Psychopharmacology

Restricted accessResearch articleFirst published December, 2012

Effectiveness of Palonosetron Versus Other Serotonin 5-HT3 Receptor Antagonists in Triple Antiemetic Regimens During Multiday Highly Emetogenic Chemotherapy

Kyung Im Kim, Dong Eun Lee, Inhye Cho [...]

Annals of Pharmacotherapy

Open accessResearch articleFirst published December, 2016

5-HT3 receptor antagonists for the prevention of postoperative shivering: a meta-analysis

Chengmao Zhou, Yu Zhu, Zhen Liu [...]

Journal of International Medical Research

Restricted accessResearch articleFirst published August, 2006

Cilansetron: A New Selective Serotonin Type 3 (5-HT3)-Receptor Antagonist for the Treatment of Irritable Bowel Syndrome in Males and Females

Brent A. Albertson

Hospital Pharmacy

Free accessResearch articleFirst published September, 2015

Beyond the 5-HT3 receptors

S Khalifeh, G Fakhfouri, SE Mehr [...]

Human & Experimental Toxicology

Restricted accessResearch articleFirst published September, 2017

Economic evaluation of 5-HT3 receptor antagonists in combination with dexamethasone for the prevention of ‘overall’ nausea and vomiting following highly emetogenic chemotherapy in Chinese adult patients

Qiong Du, Qing Zhai, Bin Zhu [...]

Journal of Oncology Pharmacy Practice

Restricted accessResearch articleFirst published December, 1990

Prevention of Nausea and Vomiting in Cisplatin-Treated Patients by a Selective 5-Hydroxytryptamine (5-HT3) Receptor Antagonist,ICS 205-930

Luigi Dogliotti, Roberto Faggiuolo, Alfredo Berruti [...]

Tumori Journal

Restricted accessOtherFirst published January, 2004

Cancer Patients Submitted to Innovative Chemotherapeutic Agents of Intermediate Emetogenic Potential: Antiemetic Prescriptions and Incidence of Emesis

Verena De Angelis

Tumori Journal

Restricted accessCase reportFirst published June, 2012

Possible anaphylaxis to palonoestron

John M Pietkiewicz

Journal of Oncology Pharmacy Practice